Infectious Diseases Laboratories (ID Labs), Agency for Science, Technology and Research (A∗STAR), Immunos, Biopolis, Singapore 138648, Singapore.
Singapore Immunology Network, Agency for Science, Technology and Research (A∗STAR), Immunos, Biopolis, Singapore 138648, Singapore.
Cell Rep Med. 2021 Feb 16;2(2):100193. doi: 10.1016/j.xcrm.2021.100193. Epub 2021 Jan 16.
Early detection of infection is crucial to limit the spread of coronavirus disease 2019 (COVID-19). Here we develop a flow cytometry-based assay to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein antibodies in individuals with COVID-19. The assay detects specific immunoglobulin M (IgM), IgA, and IgG in individuals with COVID-19 and also acquisition of all IgG subclasses, with IgG1 being the most dominant. The antibody response is significantly higher at a later stage of infection. Furthermore, asymptomatic individuals with COVID-19 also develop specific IgM, IgA, and IgG, with IgG1 being the most dominant subclass. Although the antibody levels are lower in asymptomatic infection, the assay is highly sensitive and detects 97% of asymptomatic infections. These findings demonstrate that the assay can be used for serological analysis of symptomatic and asymptomatic infections, which may otherwise remain undetected.
早期检测感染对于限制 2019 年冠状病毒病（COVID-19）的传播至关重要。在这里，我们开发了一种基于流式细胞术的检测方法，用于检测 COVID-19 患者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突（S）蛋白抗体。该检测方法可检测 COVID-19 患者的特异性免疫球蛋白 M（IgM）、IgA 和 IgG，还可检测所有 IgG 亚类，其中 IgG1 最为主要。在感染的后期，抗体反应显著增强。此外，无症状 COVID-19 患者也会产生特异性 IgM、IgA 和 IgG，其中 IgG1 是最主要的亚类。尽管无症状感染中的抗体水平较低，但该检测方法具有高度的敏感性，可检测到 97%的无症状感染。这些发现表明，该检测方法可用于对有症状和无症状感染进行血清学分析，否则这些感染可能会被漏检。
